Palo Alto – August 29, 2016 – Cooley advised Protagonist Therapeutics on its $90 million initial public offering. The company now trades on The NASDAQ Global Market under the symbol "PTGX."

Protagonist is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs.

The Cooley corporate and securities team advising Protagonist included Mike Tenta, Kenn Guernsey, Glen Sato, Josh Seidenfeld, Pete Mandel, Jared Verzello and Mei Li.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.